Comparative Pharmacology
Head-to-head clinical analysis: ALPHAGAN versus IOPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALPHAGAN versus IOPIDINE.
ALPHAGAN vs IOPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
Alpha-2 adrenergic agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
1 drop of 0.1% or 0.15% solution in the affected eye(s) three times daily, approximately 8 hours apart.
Adults: 1 drop of 0.5% or 1% ophthalmic solution in the affected eye(s) three times daily, beginning 48 hours prior to surgery and continuing on the day of surgery. Alternatively, for intraocular surgery, 1 drop of 1% solution is administered 1 hour before surgery and 1 drop immediately after surgery.
None Documented
None Documented
2.5-3.0 hours in adults; in renal impairment, half-life is prolonged (up to 6 hours).
0.5-2 hours (terminal) for topical ophthalmic administration; clinical effect may persist longer due to local tissue binding.
Renal: approximately 70-80% as unchanged drug and metabolites; fecal: 5-10%.
Renal excretion (% unchanged drug not determined; metabolites excreted renally)
Category C
Category C
Alpha-2 Agonist
Alpha-2 Agonist